BONESUPPORT Inc. Announces Partnership with Academy Medical

Boston, US 08:00 ET 28 August 2019. BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, is pleased to announce a new partnership with Academy Medical to market CERAMENT® BONE VOID FILLER in Veterans Administration (VA) and Department of Defense (DOD) Hospitals.


CERAMENT is an innovative and industry-leading synthetic bone graft substitute that promotes healing of bone voids and fractures caused by trauma, infection or disease. Academy Medical’s goal is to provide the most advanced medical and surgical products to help the federal government ensure the best healthcare possible for veterans, active military members, and their families. Academy Medical works with their extensive network of vendors to provide access to government contracts and open sales channels, to ensure the most advanced technology is readily available to government clinicians and medical facilities across the country.


“We believe our partnership with Academy Medical will greatly impact the rapid growth of our U.S. business by leveraging the immediate opportunity for CERAMENT at the numerous VA and DOD hospitals.” says BONESUPPORT CEO Emil Billbäck.


For more information contact:

Patrick O’Donnell
G.M. & E.V.P of Commercial Operations
T: 1.781.943.3452



BONESUPPORT Inc. is located in Boston and is a wholly owned subsidiary of BONESUPPORT AB. BONESUPPORT develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for its gentamicin eluting product is planned in 2021.


Please visit for more information.


BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.